悪性中皮腫市場：薬剤タイプ、治療タイプ、投与経路、流通別-2025～2030年の世界予測

悪性中皮腫市場は、2023年に7億7,267万米ドルと評価され、2024年には8億3,443万米ドルに達すると予測され、CAGR 8.26%で成長し、2030年には13億4,715万米ドルに達すると予測されています。

アスベスト暴露に主に関連する希少で攻撃的なタイプのがんである悪性中皮腫は、その市場範囲と定義を確認するため、市場調査領域で幅広く調査しています。この疾患は予後不良のため、効果的な治療と予防戦略のための継続的な調査が必要です。この市場には、患者の予後改善を目的とした医薬品開発、診断の進歩、治療手順への応用が含まれます。主要エンドユーザーは、医療プロバイダー、研究機関、製薬会社です。市場成長の主要要因は、アスベスト使用に対する意識の高まりと厳しい規制の枠組み、さらに医療研究と技術の進歩です。しかし、治療費の高騰、早期診断の制限、患者数の少なさといった課題が、市場拡大の妨げとなっています。最新のビジネス機会は、革新的な免疫療法と遺伝子治療の開発にあり、これらは牽引役となっています。バイオテクノロジー企業と医療機関の戦略的提携は、新しい治療の臨床検査と市場参入を迅速に進める上で最も重要です。さらに、遺伝子プロファイリング別の個別化医療は、より優れた有効性のためにオーダーメイドの治療を提供し、疾病管理に革命をもたらす可能性があります。多大な研究投資にもかかわらず、現在の治療法に対する耐性や疾患メカニズムの複雑さなど、限界は依然として存在します。このため、新たな治療手段や分子生物学的研究の継続的な探求が必要です。中皮腫市場の性質は、画期的な治療と効率的な診断ソリューションの緊急の必要性によって、高度に専門化され、競争しているように見えます。早期発見、費用対効果の高い治療法、患者ケア経路の改善につながるイノベーションは、市場環境に大きな影響を与えるであると考えられます。利害関係者は、診断精度と治療の個別化を強化するために、パートナーシップを育み、人工知能や機械学習などの技術的進歩を活用することに注力すべきです。

市場力学：急速に進化する悪性中皮腫市場の主要市場洞察を公開

悪性中皮腫市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネス機会の獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の悪性中皮腫罹患率の上昇
  • 悪性中皮腫治療のための臨床検査数の増加
  • 悪性中皮腫治療のための診断・予後バイオマーカーの使用
• 市場抑制要因
  • 悪性中皮腫の外科治療にかかる費用の高さ
• 市場機会
  • 悪性中皮腫治療のための新規治療法の採用
  • 悪性中皮腫研究のための有利な資金状況
• 市場課題
  • 悪性中皮腫治療に伴う副作用

ポーターのファイブフォース：悪性中皮腫市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、悪性中皮腫市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：悪性中皮腫市場における外部からの影響の把握

外部マクロ環境要因は、悪性中皮腫市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：悪性中皮腫市場における競合情勢の把握

悪性中皮腫市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：悪性中皮腫市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、悪性中皮腫市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：悪性中皮腫市場における成功への道筋を描く

悪性中皮腫市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力を評価します。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で悪性中皮腫の発生率が上昇
    • 悪性中皮腫の治療に関する臨床検査数の増加
    • 悪性中皮腫治療における診断と予後バイオマーカーの使用
  • 抑制要因
    • 悪性中皮腫外科治療の高額な費用
  • 機会
    • 悪性中皮腫の治療のための新しい治療法の採用
    • 悪性中皮腫に関する調査に対する好ましい資金調達情勢
  • 課題
    • 悪性中皮腫の治療に伴う副作用
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 悪性中皮腫市場：薬剤タイプ別

• イントロダクション
• カルボプラチン
• シスプラチン
• ゲムシタビン
• ペメトレキセド
• ビノレルビン

第7章 悪性中皮腫市場：治療タイプ別

• イントロダクション
• 化学療法
  • 局所化学療法
  • 全身化学療法
• 免疫療法
• 標的療法

第8章 悪性中皮腫市場：投与経路別

• イントロダクション
• 経口
• 非経口

第9章 悪性中皮腫市場：流通別

• イントロダクション
• 病院薬局
• オンライン薬局
• 小売薬局

第10章 南北アメリカの悪性中皮腫市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋の悪性中皮腫市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの悪性中皮腫市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Advanz Pharma Corp.
• Argenx SE
• AstraZeneca Plc
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• Cipla Limited
• Dr. Reddy's Laboratories
• Eisai Co., Ltd.
• Eli Lilly and Company
• Emcure Pharmaceuticals Limited
• F. Hoffmann-La Roche Ltd.
• Fresenius Kabi AG
• Karyopharm Therapeutics Inc.
• Merck & Co., Inc.
• Mylan N.V.
• Nichi-Iko Pharmaceutical Co., Ltd.
• Novartis AG
• Novocure GmbH
• Ono Pharmaceutical Co. Ltd.
• Pfizer Inc.
• Polaris Pharmaceuticals, Inc.
• Sanofi S.A.
• Sun Pharmaceuticals Industries Ltd.
• Wellona Pharma

LIST OF FIGURES

• FIGURE 1. MALIGNANT MESOTHELIOMA MARKET RESEARCH PROCESS
• FIGURE 2. MALIGNANT MESOTHELIOMA MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. MALIGNANT MESOTHELIOMA MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. MALIGNANT MESOTHELIOMA MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. MALIGNANT MESOTHELIOMA MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. MALIGNANT MESOTHELIOMA MARKET DYNAMICS
• TABLE 7. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CARBOPLATIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CISPLATIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY GEMCITABINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PEMETREXED, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY VINORELBINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY LOCAL CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY SYSTEMIC CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY HOSPITALS PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 43. CANADA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 44. CANADA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 45. CANADA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 46. CANADA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 47. CANADA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 48. MEXICO MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 49. MEXICO MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 51. MEXICO MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 52. MEXICO MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 53. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 54. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 59. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 60. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 64. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 65. AUSTRALIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 66. AUSTRALIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 68. AUSTRALIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 69. AUSTRALIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 70. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 71. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 72. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 73. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 74. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 75. INDIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 76. INDIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 77. INDIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 78. INDIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 79. INDIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 80. INDONESIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 81. INDONESIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 82. INDONESIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 83. INDONESIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 84. INDONESIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 85. JAPAN MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 86. JAPAN MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 87. JAPAN MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 88. JAPAN MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 89. JAPAN MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 90. MALAYSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 91. MALAYSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 92. MALAYSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 93. MALAYSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 94. MALAYSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 95. PHILIPPINES MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 96. PHILIPPINES MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 97. PHILIPPINES MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 98. PHILIPPINES MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 99. PHILIPPINES MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 100. SINGAPORE MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 101. SINGAPORE MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 102. SINGAPORE MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 103. SINGAPORE MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 104. SINGAPORE MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 105. SOUTH KOREA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 106. SOUTH KOREA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 107. SOUTH KOREA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 108. SOUTH KOREA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 109. SOUTH KOREA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 110. TAIWAN MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 111. TAIWAN MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 112. TAIWAN MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 113. TAIWAN MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 114. TAIWAN MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 115. THAILAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 116. THAILAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 117. THAILAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 118. THAILAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 119. THAILAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 120. VIETNAM MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 121. VIETNAM MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 122. VIETNAM MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 123. VIETNAM MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 124. VIETNAM MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 125. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 126. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 127. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 129. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 130. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 131. DENMARK MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 132. DENMARK MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 133. DENMARK MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 134. DENMARK MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 135. DENMARK MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 136. EGYPT MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 137. EGYPT MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 138. EGYPT MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 139. EGYPT MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 140. EGYPT MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 141. FINLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 142. FINLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 143. FINLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 144. FINLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 145. FINLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 146. FRANCE MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 147. FRANCE MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 148. FRANCE MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 149. FRANCE MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 150. FRANCE MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 151. GERMANY MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 152. GERMANY MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 153. GERMANY MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 154. GERMANY MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 155. GERMANY MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 156. ISRAEL MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 157. ISRAEL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 158. ISRAEL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 159. ISRAEL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 160. ISRAEL MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 161. ITALY MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 162. ITALY MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 163. ITALY MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 164. ITALY MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 165. ITALY MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 166. NETHERLANDS MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 167. NETHERLANDS MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 168. NETHERLANDS MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 169. NETHERLANDS MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 170. NETHERLANDS MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 171. NIGERIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 172. NIGERIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 173. NIGERIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 174. NIGERIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 175. NIGERIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 176. NORWAY MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 177. NORWAY MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 178. NORWAY MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 179. NORWAY MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 180. NORWAY MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 181. POLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 182. POLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 183. POLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 184. POLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 185. POLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 186. QATAR MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 187. QATAR MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 188. QATAR MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 189. QATAR MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 190. QATAR MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 191. RUSSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 192. RUSSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 193. RUSSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 194. RUSSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 195. RUSSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 196. SAUDI ARABIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 197. SAUDI ARABIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 198. SAUDI ARABIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 199. SAUDI ARABIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 200. SAUDI ARABIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 201. SOUTH AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 206. SPAIN MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 207. SPAIN MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 208. SPAIN MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 209. SPAIN MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 210. SPAIN MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 211. SWEDEN MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 212. SWEDEN MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 213. SWEDEN MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 214. SWEDEN MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 215. SWEDEN MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 216. SWITZERLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 217. SWITZERLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 218. SWITZERLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 219. SWITZERLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 220. SWITZERLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 221. TURKEY MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 222. TURKEY MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 223. TURKEY MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 224. TURKEY MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 225. TURKEY MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 226. UNITED ARAB EMIRATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 227. UNITED ARAB EMIRATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 228. UNITED ARAB EMIRATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 229. UNITED ARAB EMIRATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 230. UNITED ARAB EMIRATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 231. UNITED KINGDOM MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 232. UNITED KINGDOM MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 234. UNITED KINGDOM MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 235. UNITED KINGDOM MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 236. MALIGNANT MESOTHELIOMA MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 237. MALIGNANT MESOTHELIOMA MARKET, FPNV POSITIONING MATRIX, 2023

The Malignant Mesothelioma Market was valued at USD 772.67 million in 2023, expected to reach USD 834.43 million in 2024, and is projected to grow at a CAGR of 8.26%, to USD 1,347.15 million by 2030.

Malignant Mesothelioma, a rare and aggressive type of cancer associated predominantly with asbestos exposure, is being extensively studied within the market research realm to ascertain its market scope and definition. This condition necessitates ongoing research for effective treatments and preventative strategies due to its poor prognosis. The market includes applications in pharmaceutical developments, diagnostic advancements, and therapeutic procedures aimed at improving patient outcomes. Key end-users comprise healthcare providers, research institutions, and pharmaceutical companies. Market growth is primarily influenced by increasing awareness and stringent regulatory frameworks for asbestos use, coupled with advances in medical research and technology. However, challenges such as the high cost of treatment, limited early diagnosis, and a relatively small patient population hinder the market expansion. Latest opportunities lie in innovative immunotherapy and gene therapy developments which are gaining traction. Strategic collaborations between biotechnology firms and healthcare organizations are paramount to fast-tracking clinical trials and market entry for new treatments. Additionally, personalized medicine based on genetic profiling could revolutionize the management of the disease, offering tailored treatment for better efficacy. Despite significant research investments, limitations persist in the form of resistance to current treatments and the complexity of disease mechanisms. This necessitates continued exploration into novel therapeutic avenues and molecular research. The nature of the mesothelioma market appears to be highly specialized and competitive, driven by the urgent need for breakthrough treatments and efficient diagnostic solutions. Innovations that could lead to early detection, cost-effective therapies, and improved patient care pathways stand to significantly impact the market landscape. Stakeholders should focus on fostering partnerships and leveraging technological advancements such as artificial intelligence and machine learning to enhance diagnostic precision and treatment personalization.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Malignant Mesothelioma Market

The Malignant Mesothelioma Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising incidence of malignant mesothelioma worldwide
  • Increase in the number of clinical trials for the treatment of malignant mesothelioma
  • Use of diagnostic and prognostic biomarkers for malignant mesothelioma treatment
• Market Restraints
  • High cost of malignant mesothelioma surgical treatment
• Market Opportunities
  • Introduction of novel therapies for the treatment of malignant mesothelioma
  • Favorable funding landscape for research on malignant mesothelioma
• Market Challenges
  • Adverse effects associated with the treatment of malignant mesothelioma

Porter's Five Forces: A Strategic Tool for Navigating the Malignant Mesothelioma Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Malignant Mesothelioma Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Malignant Mesothelioma Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Malignant Mesothelioma Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Malignant Mesothelioma Market

A detailed market share analysis in the Malignant Mesothelioma Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Malignant Mesothelioma Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Malignant Mesothelioma Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Malignant Mesothelioma Market

A strategic analysis of the Malignant Mesothelioma Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Malignant Mesothelioma Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Advanz Pharma Corp., Argenx SE, AstraZeneca Plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cipla Limited, Dr. Reddy's Laboratories, Eisai Co., Ltd., Eli Lilly and Company, Emcure Pharmaceuticals Limited, F. Hoffmann-La Roche Ltd., Fresenius Kabi AG, Karyopharm Therapeutics Inc., Merck & Co., Inc., Mylan N.V., Nichi-Iko Pharmaceutical Co., Ltd., Novartis AG, Novocure GmbH, Ono Pharmaceutical Co. Ltd., Pfizer Inc., Polaris Pharmaceuticals, Inc., Sanofi S.A., Sun Pharmaceuticals Industries Ltd., and Wellona Pharma.

Market Segmentation & Coverage

This research report categorizes the Malignant Mesothelioma Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Type, market is studied across Carboplatin, Cisplatin, Gemcitabine, Pemetrexed, and Vinorelbine.
• Based on Treatment Type, market is studied across Chemotherapy, Immunotherapy, and Targeted therapy. The Chemotherapy is further studied across Local Chemotherapy and Systemic Chemotherapy.
• Based on Route of Administration, market is studied across Oral and Parenteral.
• Based on Distribution, market is studied across Hospitals Pharmacies, Online Pharmacies, and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising incidence of malignant mesothelioma worldwide
    • 5.1.1.2. Increase in the number of clinical trials for the treatment of malignant mesothelioma
    • 5.1.1.3. Use of diagnostic and prognostic biomarkers for malignant mesothelioma treatment
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of malignant mesothelioma surgical treatment
  • 5.1.3. Opportunities
    • 5.1.3.1. Introduction of novel therapies for the treatment of malignant mesothelioma
    • 5.1.3.2. Favorable funding landscape for research on malignant mesothelioma
  • 5.1.4. Challenges
    • 5.1.4.1. Adverse effects associated with the treatment of malignant mesothelioma
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Malignant Mesothelioma Market, by Drug Type

• 6.1. Introduction
• 6.2. Carboplatin
• 6.3. Cisplatin
• 6.4. Gemcitabine
• 6.5. Pemetrexed
• 6.6. Vinorelbine

7. Malignant Mesothelioma Market, by Treatment Type

• 7.1. Introduction
• 7.2. Chemotherapy
  • 7.2.1. Local Chemotherapy
  • 7.2.2. Systemic Chemotherapy
• 7.3. Immunotherapy
• 7.4. Targeted therapy

8. Malignant Mesothelioma Market, by Route of Administration

• 8.1. Introduction
• 8.2. Oral
• 8.3. Parenteral

9. Malignant Mesothelioma Market, by Distribution

• 9.1. Introduction
• 9.2. Hospitals Pharmacies
• 9.3. Online Pharmacies
• 9.4. Retail Pharmacies

10. Americas Malignant Mesothelioma Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Malignant Mesothelioma Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Malignant Mesothelioma Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Advanz Pharma Corp.
• 3. Argenx SE
• 4. AstraZeneca Plc
• 5. Boehringer Ingelheim GmbH
• 6. Bristol-Myers Squibb Company
• 7. Cipla Limited
• 8. Dr. Reddy's Laboratories
• 9. Eisai Co., Ltd.
• 10. Eli Lilly and Company
• 11. Emcure Pharmaceuticals Limited
• 12. F. Hoffmann-La Roche Ltd.
• 13. Fresenius Kabi AG
• 14. Karyopharm Therapeutics Inc.
• 15. Merck & Co., Inc.
• 16. Mylan N.V.
• 17. Nichi-Iko Pharmaceutical Co., Ltd.
• 18. Novartis AG
• 19. Novocure GmbH
• 20. Ono Pharmaceutical Co. Ltd.
• 21. Pfizer Inc.
• 22. Polaris Pharmaceuticals, Inc.
• 23. Sanofi S.A.
• 24. Sun Pharmaceuticals Industries Ltd.
• 25. Wellona Pharma